Decision models in the evaluation of psychotropic drugs
- 1 September 2006
- journal article
- editorial
- Published by Springer Science and Business Media LLC in The European Journal of Health Economics
- Vol. 7 (3), 218-220
- https://doi.org/10.1007/s10198-006-0348-z
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in GermanyThe European Journal of Health Economics, 2006
- Risperidone versus olanzapine for schizophreniaEmergencias, 2006
- Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional studyDiabetologia, 2005
- An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophreniaControlled Clinical Trials, 2004
- Components of a modern mental health service: a pragmatic balance of community and hospital careThe British Journal of Psychiatry, 2004
- "Wish Bias" in Antidepressant Drug Trials?Journal of Clinical Psychopharmacology, 2004
- Psychotropic Drug Use in Psychiatric Inpatients: Recent Trends and Changes over Time-Data from the AMSP StudyPharmacopsychiatry, 2004
- Adverse Metabolic Effects Associated with Atypical AntipsychoticsDrugs, 2004
- The iceberg tip and the rest. Mental health care for people with schizophrenia in five European centresEpidemiologia e Psichiatria Sociale, 2002
- A Comparison of Risperidone and Haloperidol for the Prevention of Relapse in Patients with SchizophreniaNew England Journal of Medicine, 2002